Genenta, 11-member pact to return to research and gene therapy

Renew the board of directors and return to the original corporate purpose. It is with this objective in mind that 11 shareholders of Genenta science Spa, representing approximately one third of the voting rights and one quarter of the shares, filed a single Schedule 13D with the SEC, i.e. an application indicating a co-ordinated stake in the company. The application was filed with the SEC because the company is listed on the Nasdaq.

Genenta started out as a San Raffaele start-up focusing on gene therapy to fight cancer and has recently undergone a turnaround that has changed its original corporate purpose.

In October 2025, Chairman, CEO and co-founder Pierluigi Paracchi decided to make two defence acquisitions, one of a precision rifle company, the other in aerospace.

However, the turn was not shared by an important group of shareholders, including Genenta's geneticist and co-founder Luigi Naldini, who publicly declared at the time that the decision had been taken without his consent. In the meantime, other shareholders, equally at odds with the decision, have turned to the Court of Milan to challenge the new course set by the old board of directors and declare the October shareholders' meeting null and void. A hearing is expected in a few days.

Yesterday, there was news that a group of 11 shareholders had formed a pact and asked the SEC to investigate the legality of the transaction and to renew the board of directors. The purpose of the request is to bring about the coordinated participation of the group of shareholders in opposition to the turnaround in the defence. We are talking about eleven investors, including private individuals and Italian investment companies, who have declared effective ownership of 5,433,910 Ordinary Shares and Ads, equal to approximately 23% of the shares and 31.5% of the total voting rights. This is the picture taken on 19 March 2026.